Drug Kamuvudine-9 Reversed MS Symptoms in Mice
Researchers found that a non-toxic derivative of NRTIs protected myelin and repaired motor function in animal models.
Updated on Sept. 23, 2026 in Stroke
Live Poll
Do you trust that repurposing existing medications is an effective strategy for developing new disease treatments?
A study published in Science Translational Medicine showed that the drug kamuvudine-9 (K-9) reversed vision loss and paralysis in mice with multiple sclerosis. The findings build on a patient analysis that linked NRTI use to lower rates of MS diagnosis and relapse.
Why it matters
The research identifies a potential new therapeutic pathway for multiple sclerosis by preventing inflammasome activation in the central nervous system. By shielding axons and myelin from degeneration, this treatment may eventually offer a way to stop or reverse neurological damage.
A study analyzed insurance claims from 3 million U.S. patients, demonstrating lower MS diagnosis and relapse rates among those taking NRTIs. Treated mice showed reduced levels of the neurofilament light chain biomarker compared to untreated subjects.
The players
University of Virginia
This public research university in Charlottesville, Virginia, served as the site for the MS research study.
The details
University of Virginia researchers developed K-9 by removing the antiviral properties of existing NRTIs to create a non-toxic compound. The study found that administering the drug over two weeks effectively protected myelin sheaths and reversed motor impairment in induced MS-like models.
Timeline
September 23, 2026: Study findings were published in Science Translational Medicine.
The Big Picture
This research parallels the National Eye Institute's inflammatory eye disease research programs by targeting the same underlying inflammasome activation processes. The study extends current medical understanding of how inflammasome pathways contribute to neurodegeneration.
This development could eventually lead to new treatment options for MS patients that focus on reversing rather than just managing neurodegeneration. While the drug has been tested for other conditions like thyroid eye disease, patients should await formal clinical trials before expecting availability.
The takeaway
K-9 represents a novel approach to treating MS by disabling the inflammasome that drives nerve damage. Future research will determine if these promising results in animal models can be safely translated into human therapy.
What happens next
Researchers are planning to initiate clinical studies to test the safety and efficacy of kamuvudine-9 in human patients for both multiple sclerosis and ALS.
Further reading
For additional context on neurological health and related breakthroughs, visit the United States Stroke section.
More information
To learn more about eye and neurological research, visit the National Eye Institute information portal.
Live Poll
Do you trust that repurposing existing medications is an effective strategy for developing new disease treatments?
